BONIDE PRODUCTS LLC – Trademark Portfolio
Entity Type: 16
BONIDE PRODUCTS LLC holds 28 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 25 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 26 trademarks are registered. Notable registered marks include MITE-X, BURNOUT, MOLETOX, REVENGE, and VITAL-X. The owner is based in ORISKANY, NY.
6301 SUTLIFF ROAD
ORISKANY, NY 13424
Showing of trademarks Trademarks
Trademark Classifications
BONIDE PRODUCTS LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Common metals and their alloys; metal building materials; transportable buildings of metal
Frequently Asked Questions
How many trademarks does BONIDE PRODUCTS LLC have?
BONIDE PRODUCTS LLC has 28 U.S. trademarks filed with the USPTO. Of these, 26 registered, 2 abandoned.
What trademark classes does BONIDE PRODUCTS LLC file in?
BONIDE PRODUCTS LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 21 (Housewares), Class 6 (Metal Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are BONIDE PRODUCTS LLC's most well-known trademarks?
BONIDE PRODUCTS LLC's registered trademark portfolio includes well-known marks such as MITE-X, BURNOUT, MOLETOX, REVENGE, and VITAL-X. These are among 26 currently registered trademarks in the portfolio.
What is BONIDE PRODUCTS LLC's trademark registration success rate?
BONIDE PRODUCTS LLC has a 93% trademark registration rate, with 26 out of 28 resolved applications resulting in successful registration. Currently, 0 applications are pending review.